Recent news highlights DexCom's strong Q1 2026 financial performance with revenue and earnings growth, margin improvements, and profit advances.

• DexCom reported Q1 2026 revenue of $1.19 billion, a 15% increase year-over-year, with gross profit rising 27% to $750.3 million and operating income increasing 91% to $255.3 million [N2][N4].
• Net income for Q1 2026 was $199.5 million, up 89% from the prior year period, with basic EPS of $0.52 and diluted EPS of $0.51 [N2][N5].
• The company ended Q1 2026 with cash, cash equivalents, and short-term marketable securities totaling approximately $2.42 billion, supporting liquidity and operational flexibility [N2].
• DexCom continues to invest in research and development and selling, general and administrative expenses, reflecting ongoing innovation and market expansion efforts [N2].
• The company maintains partnerships with insulin pump companies and is exploring new applications for its technology in broader metabolic health areas [N3].

DexCom's expanding product portfolio, including the recent launch of the G7 15 Day system and Stelo biosensor, positions it to address broader patient segments such as prediabetes and Type 2 diabetes. Its focus on integrating CGM data with predictive analytics and partnerships with insulin delivery and consumer technology companies could enhance patient engagement and adherence. Strong financial performance with rising revenues, improving margins, and robust liquidity supports ongoing investment in innovation and market expansion.

DexCom faces risks from competitive pressures in the medical device and CGM markets, including pricing pressures and technological advancements by competitors. The company’s revenue is subject to seasonality and reimbursement dynamics, which may impact sales consistency. Inventory obsolescence charges indicate challenges in managing product lifecycle and demand forecasting. Regulatory changes or delays in product approvals could affect growth. Additionally, reliance on partnerships and distribution channels introduces execution risks.

DexCom's competitive advantage stems from its early FDA approvals and established presence in the CGM market, supported by continuous product innovation such as the G7 system and Stelo biosensor. Its integrated sales approach combining direct and distributor channels facilitates broad market reach. Partnerships with insulin pump and consumer technology companies enhance its ecosystem and product connectivity. The company's investment in data analytics and machine learning to generate predictive insights further differentiates its offerings. High barriers to entry exist due to regulatory approvals, technological complexity, and established customer relationships.

• Competitive and Pricing Pressure: DexCom operates in a competitive medical device market with potential pricing pressures that could impact margins and market share.
• Regulatory and Product Development Risks: Delays or challenges in obtaining regulatory approvals for new products or enhancements could affect product launches and revenue growth.
• Inventory and Supply Chain Management: Inventory obsolescence charges suggest risks related to product demand forecasting and supply chain efficiency.
• Reimbursement and Market Dynamics: Changes in insurance reimbursement policies and seasonality in sales due to deductible resets may affect revenue stability.

• DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management globally.
• The company launched its first FDA-approved product in 2006 and has since introduced the Dexcom G7 CGM system in 2023 and the G7 15 Day system in late 2025.
• In August 2024, DexCom launched Stelo, an over-the-counter glucose biosensor targeting adults with prediabetes and Type 2 diabetes who do not use insulin.
• DexCom sells its products through a direct sales organization in North America and certain international markets, complemented by distribution arrangements allowing third-party distributors to sell its products.
• Revenue is generated primarily from disposable sensors and reusable hardware (transmitters and receivers).
• The company experiences seasonality in sales, with lower sales in Q1 due to U.S. insurance deductible resets and flexible spending account factors.
• For the quarter ended March 31, 2026, DexCom reported revenue of $1.19 billion, a 15% increase from the same period in 2025.
• Gross profit for Q1 2026 was $750.3 million, up 27% year-over-year, with a gross margin of approximately 62.9%.
• Operating income for Q1 2026 was $255.3 million, a 91% increase compared to Q1 2025.
• Net income for Q1 2026 was $199.5 million, up 89% from the prior year period.
• Basic earnings per share for Q1 2026 were $0.52, and diluted EPS was $0.51.
• The company ended Q1 2026 with cash, cash equivalents, and short-term marketable securities totaling approximately $2.42 billion.
• Liquidity ratios as of March 31, 2026, include a current ratio of 1.95 and a cash ratio of 0.62, indicating solid short-term financial health.
• DexCom operates as a single reportable segment globally, with the majority of revenue generated in the United States.
• For Q1 2026, revenue by sales channel was $1.01 billion via distributors and $181.6 million via direct sales, with international revenue totaling $359.6 million.
• Research and development expenses for Q1 2026 were $145.3 million, consistent with the prior year period.
• Selling, general and administrative expenses increased to $349.7 million in Q1 2026 from $310.1 million in Q1 2025.
• The company recorded excess and obsolete inventory charges of $38.6 million in Q1 2026, reflecting ongoing product innovation and quality control evaluations.
• DexCom maintains partnerships with insulin pump companies and is exploring applications beyond glucose monitoring, including metabolic health insights and other patient populations such as prediabetes, obesity, pregnancy, and hospital settings.
• The company has a share repurchase program authorized in 2025 but did not repurchase shares in Q1 2026.
• DexCom's financial statements and disclosures comply with GAAP and are filed with the SEC, with the latest quarterly report filed on April 30, 2026.